Literature DB >> 22980449

Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model.

Patricia A Pade1, Karen E Cardon, Richard M Hoffman, Cynthia M A Geppert.   

Abstract

Abuse of opioids has become a public health crisis. The historic separation between the addiction and pain communities and a lack of training in medical education have made treatment difficult to provide, especially in primary care. The Co-occurring Disorders Clinic (COD) was established to treat patients with co-morbid chronic pain and addiction. This retrospective chart review reports results of a quality improvement project using buprenorphine/naloxone to treat co-occurring chronic non-cancer pain (CNCP) and opioid dependence in a primary care setting. Data were collected for 143 patients who were induced with buprenorphine/naloxone (BUP/NLX) between June 2009 and November 2011. Ninety-three patients (65%) continued to be maintained on the medication and seven completed treatment and were no longer taking any opioid (5%). Pain scores showed a modest, but statistically significant improvement on BUP/NLX, which was contrary to our expectations and may be an important factor in treatment retention for this challenging population. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22980449     DOI: 10.1016/j.jsat.2012.08.010

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  18 in total

1.  Integrated Behavioral Treatment for Veterans With Co-Morbid Chronic Pain and Hazardous Opioid Use: A Randomized Controlled Pilot Trial.

Authors:  Kevin E Vowles; Katie Witkiewitz; Karen J Cusack; Wesley P Gilliam; Karen E Cardon; Sarah Bowen; Karlyn A Edwards; Mindy L McEntee; Robert W Bailey
Journal:  J Pain       Date:  2019-11-21       Impact factor: 5.820

2.  Effects of craving on opioid use are attenuated after pain coping counseling in adults with chronic pain and prescription opioid addiction.

Authors:  Bryan G Messina; Matthew J Worley
Journal:  J Consult Clin Psychol       Date:  2019-10

Review 3.  Buprenorphine-naloxone therapy in pain management.

Authors:  Kelly Yan Chen; Lucy Chen; Jianren Mao
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

4.  Pharmacological attenuation of chronic alcoholic pancreatitis induced hypersensitivity in rats.

Authors:  Sabrina L McIlwrath; Karin N Westlund
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

5.  Pressure sensitivity and phenotypic changes in patients with suspected opioid-induced hyperalgesia being withdrawn from full mu agonists.

Authors:  Ronald A Wasserman; Afton L Hassett; Steven E Harte; Jenna Goesling; Herbert L Malinoff; Daniel W Berland; Jennifer Zollars; Stephanie E Moser; Chad M Brummett
Journal:  J Nat Sci       Date:  2017-02

6.  Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use.

Authors:  Kaitlyn R Hay; Andrew S Huhn; David Andrew Tompkins; Kelly E Dunn
Journal:  J Addict Med       Date:  2019 Jul/Aug       Impact factor: 3.702

Review 7.  Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

8.  Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.

Authors:  Matthew J Worley; Keith G Heinzerling; Steven Shoptaw; Walter Ling
Journal:  Addiction       Date:  2017-02-28       Impact factor: 6.526

9.  Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Authors:  Perrine Roux; Maria A Sullivan; Julien Cohen; Lionel Fugon; Jermaine D Jones; Suzanne K Vosburg; Ziva D Cooper; Jeanne M Manubay; Shanthi Mogali; Sandra D Comer
Journal:  Pain       Date:  2013-05-07       Impact factor: 6.961

10.  Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.

Authors:  Matthew J Worley; Keith G Heinzerling; Steven Shoptaw; Walter Ling
Journal:  Exp Clin Psychopharmacol       Date:  2015-08-24       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.